
-
02/09/2016
PAION discontinues European Remimazolam Phase III Trial in cardiac surgery patients due to insufficient recruitment
-
02/18/2016
PAION reports about positive pre-NDA meeting with Japanese authority PMDA
-
04/11/2016
PAION successfully completes patient recruitment in Phase III study with Remimazolam for procedural sedation during colonoscopy
-
06/19/2016
PAION reports positive remimazolam headline data in pivotal U.S. Phase III study in procedural sedation for colonoscopy
-
06/24/2016
PAION grants Cosmo Pharmaceuticals Remimazolam license in the U.S. and Cosmo becomes largest Shareholder of PAION AG
-
12/19/2016
PAION successfully completes patient recruitment in U.S. clinical safety trial of remimazolam in high-risk patients undergoing colonoscopy